Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2941)
All Articles published online
|
Nov 21, 2007 (publication date) through Apr 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol 2007; 13(43): 5673-5681 [PMID: 17963291 DOI: 10.3748/wjg.v13.i43.5673] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i43/5673.htm |
| Number | Citing Articles |
| 1 |
Danylo Kaminskyy, Anna Kryshchyshyn, Roman Lesyk. 5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistry. European Journal of Medicinal Chemistry 2017; 140: 542 doi: 10.1016/j.ejmech.2017.09.031
|
| 2 |
Guoxing Soon, Zhiwei Zhang, Yi Tsong, Lei Nie. Assessing overall evidence from noninferiority trials with shared historical data. Statistics in Medicine 2013; 32(14): 2349 doi: 10.1002/sim.5615
|
| 3 |
Yi Zhou, Na Chen, Xiaojing Liu, Shumei Lin, Wenjuan Luo, Min Liu. Kushenin induces the apoptosis of HCV-infected cells by blocking the PI3K-Akt-mTOR pathway via inhibiting NS5A. Experimental Cell Research 2016; 345(1): 108 doi: 10.1016/j.yexcr.2016.05.002
|
| 4 |
J.-M. Sun, S.-J. Kim, G.-W. Kim, J.-K. Rhee, N. D. Kim, H. Jung, J. Jeun, S.-H. Lee, S. H. Han, C. S. Shin, J.-W. Oh. Inhibition of hepatitis C virus replication by Monascus pigment derivatives that interfere with viral RNA polymerase activity and the mevalonate biosynthesis pathway. Journal of Antimicrobial Chemotherapy 2012; 67(1): 49 doi: 10.1093/jac/dkr432
|
| 5 |
Reem Beleid, Donna Douglas, Norman Kneteman, Kamaljit Kaur. Helical Peptides Derived from Lactoferrin Bind Hepatitis C Virus Envelope Protein E2. Chemical Biology & Drug Design 2008; 72(5): 436 doi: 10.1111/j.1747-0285.2008.00715.x
|
| 6 |
Philippe A. Gallay. Cyclophilin Inhibitors. Clinics in Liver Disease 2009; 13(3): 403 doi: 10.1016/j.cld.2009.05.002
|
| 7 |
Sean M. McConachie, Sheila M. Wilhelm, Pramodini B. Kale-Pradhan. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology 2016; 9(2): 287 doi: 10.1586/17512433.2016.1129272
|
| 8 |
Yun‐Ping Lim, Cheng‐Yuan Peng, Wen‐Ling Liao, Dong‐Zong Hung, Ni Tien, Cing‐Yu Chen, Shih‐Yu Chang, Ching‐Yao Chang, Fuu‐Jen Tsai, Lei Wan. Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese. Journal of Medical Virology 2013; 85(7): 1206 doi: 10.1002/jmv.23598
|
| 9 |
Matthew A. Gregory, Michael Bobardt, Susan Obeid, Udayan Chatterji, Nigel J. Coates, Teresa Foster, Philippe Gallay, Pieter Leyssen, Steven J. Moss, Johan Neyts, Mohammad Nur-e-Alam, Jan Paeshuyse, Mahmood Piraee, Dipen Suthar, Tony Warneck, Ming-Qiang Zhang, Barrie Wilkinson. Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin Family. Antimicrobial Agents and Chemotherapy 2011; 55(5): 1975 doi: 10.1128/AAC.01627-10
|
| 10 |
Ivan Gentile, Antonio Riccardo Buonomo, Guglielmo Borgia. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 2014; 12(9): 1033 doi: 10.1586/14787210.2014.940898
|
| 11 |
Hongwei Wang, Haili Gao, Shupeng Duan, Xinwen Song. Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway. Virus Research 2015; 208: 7 doi: 10.1016/j.virusres.2015.05.002
|
| 12 |
Stephanie Jiménez Irausquin, Austin L. Hughes. Distinctive pattern of sequence polymorphism in the NS3 protein of hepatitis C virus type 1b reflects conflicting evolutionary pressures. Journal of General Virology 2008; 89(8): 1921 doi: 10.1099/vir.0.2008/000992-0
|
| 13 |
Guoxing G Soon, Lei Nie, Thomas Hammerstrom, Wen Zeng, Haitao Chu. Meeting the demand for more sophisticated study designs. A proposal for a new type of clinical trial: the hybrid design. BMJ Open 2011; 1(2): e000156 doi: 10.1136/bmjopen-2011-000156
|
| 14 |
Amira A. Boseila, Amal Y. Abdel-Reheem, Emad B. Basalious, Abdelwahab Omri. Design of bile-based vesicles (BBVs) for hepatocytes specific delivery of Daclatasvir: Comparison of ex-vivo transenterocytic transport, in-vitro protein adsorption resistance and HepG2 cellular uptake of charged and β-sitosterol decorated vesicles. PLOS ONE 2019; 14(7): e0219752 doi: 10.1371/journal.pone.0219752
|
| 15 |
Mohamed A.H. Ismail, Dalal A. Abou El Ella, Khaled A.M. Abouzid, Amr H. Mahmoud. Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives. Bioorganic & Medicinal Chemistry 2012; 20(7): 2455 doi: 10.1016/j.bmc.2012.01.031
|
| 16 |
Usman Ali Ashfaq, Muhammad Ansar, Muhammad Tahir Sarwar, Tariq Javed, Sidra Rehman, Sheikh Riazuddin. Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA. Virology Journal 2011; 8(1) doi: 10.1186/1743-422X-8-112
|
| 17 |
Sumalee Thitinan, Jason T. McConville. Interferon alpha delivery systems for the treatment of hepatitis C. International Journal of Pharmaceutics 2009; 369(1-2): 121 doi: 10.1016/j.ijpharm.2008.11.027
|
| 18 |
Maria Letizia Barreca, Nunzio Iraci, Giuseppe Manfroni, Violetta Cecchetti.
Allosteric Inhibition of the Hepatitis C Virus NS5B Polymerase:
In Silico
Strategies for Drug Discovery and Development
. Future Medicinal Chemistry 2011; 3(8): 1027 doi: 10.4155/fmc.11.53
|
| 19 |
Anna Kryshchyshyn-Dylevych, Danylo Kaminskyy, Roman Lesyk. In‐vitro antiviral screening of some thiopyranothiazoles. Chemico-Biological Interactions 2023; 386: 110738 doi: 10.1016/j.cbi.2023.110738
|
| 20 |
Frank Wagner, Robert Thompson, Constantino Kantaridis, Paul Simpson, Philip J. F. Troke, Shyla Jagannatha, Srividya Neelakantan, Vivek S. Purohit, Jennifer L. Hammond. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients. Hepatology 2011; 54(1): 50 doi: 10.1002/hep.24342
|
| 21 |
William W. Shields, Paul J. Pockros. Novel drugs for hepatitis C virus. Current Hepatitis Reports 2009; 8(2): 52 doi: 10.1007/s11901-009-0008-8
|
| 22 |
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Giuseppe Castaldo, Guglielmo Borgia. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opinion on Investigational Drugs 2014; 23(4): 561 doi: 10.1517/13543784.2014.892581
|
| 23 |
Carolin Wohlfarth, Thomas Efferth. Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacologica Sinica 2009; 30(1): 25 doi: 10.1038/aps.2008.5
|
| 24 |
Mozhgan Afrasiabi, Seyed Younes Hosseini, Ramin Yaghobi, Mohammad-Reza Fattahi, Maryam Ardebili, Mahboobeh Khodadad. Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran. Jundishapur Journal of Microbiology 2015; 8(10) doi: 10.5812/jjm.24965
|
| 25 |
Ivan Gentile, Nicola Coppola, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs 2014; 23(9): 1211 doi: 10.1517/13543784.2014.921680
|
| 26 |
Mahmoud Mohamed Bahgat, Ahmed Atef Ibrahim, Dina Nadeem Abd-Elshafy, Ahmed Atef Mesalam, Hossam Eid Gewaid, Amany Abd-Elghany Ismaeil, Ahmed Mohamed El-Waseef, Amany Sayed Maghraby, Ahmed Barakat Barakat, Mohamed Abd-Elhafez El-Far, Hossam El-Din Ahmed Ghanem, Amro Mahmoud Mohamed, Mohamed Ahmed Ali. Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate. Archives of Virology 2009; 154(10): 1649 doi: 10.1007/s00705-009-0500-z
|
| 27 |
Rolf Wagner, Daniel P. Larson, David W. A. Beno, Todd D. Bosse, John F. Darbyshire, Yi Gao, Bradley D. Gates, Wenping He, Rodger F. Henry, Lisa E. Hernandez, Douglas K. Hutchinson, Wen W. Jiang, Warren M. Kati, Larry L. Klein, Gennadiy Koev, William Kohlbrenner, A. Chris Krueger, Jinrong Liu, Yaya Liu, Michelle A. Long, Clarence J. Maring, Sherie V. Masse, Tim Middleton, Debra A. Montgomery, John K. Pratt, Patricia Stuart, Akhteruzzaman Molla, Dale J. Kempf. Inhibitors of Hepatitis C Virus Polymerase: Synthesis and Biological Characterization of Unsymmetrical Dialkyl-Hydroxynaphthalenoyl-benzothiadiazines. Journal of Medicinal Chemistry 2009; 52(6): 1659 doi: 10.1021/jm8010965
|
| 28 |
Partha K Chandra, Sidhartha Hazari, Bret Poat, Feyza Gunduz, Ramesh Prabhu, Gerald Liu, Roberto Burioni, Massimo Clementi, Robert F Garry, Srikanta Dash. Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virology Journal 2010; 7(1) doi: 10.1186/1743-422X-7-118
|
| 29 |
Phillip A Furman, Angela M Lam, Eisuke Murakami. Nucleoside Analog Inhibitors of Hepatitis C Viral Replication: Recent Advances, Challenges and Trends. Future Medicinal Chemistry 2009; 1(8): 1429 doi: 10.4155/fmc.09.88
|
| 30 |
Robert Flisiak, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda. Emerging treatments for hepatitis C. Expert Opinion on Emerging Drugs 2013; 18(4): 461 doi: 10.1517/14728214.2013.847089
|
| 31 |
Jerzy Jaroszewicz, Robert Flisiak, Geoffrey Dusheiko. A pill for HCV – myth or foreseeable future?. Liver International 2014; 34(1): 6 doi: 10.1111/liv.12294
|
| 32 |
Ayman Geddawy, Yasmine F. Ibrahim, Nabil M. Elbahie, Mohammad A. Ibrahim. Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction. Journal of Translational Internal Medicine 2017; 5(1): 8 doi: 10.1515/jtim-2017-0007
|
| 33 |
Yuichi HIRATA, Masayuki SUDOH, Michinori KOHARA. Suppression of Hepatitis C Virus (HCV) Replication with Serine Palmitoyltransferase Inhibitor. YAKUGAKU ZASSHI 2010; 130(2): 157 doi: 10.1248/yakushi.130.157
|
| 34 |
Ivan Gentile, Maria Aurora Carleo, Federico Borgia, Giuseppe Castaldo, Guglielmo Borgia. The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus. Expert Opinion on Investigational Drugs 2010; 19(1): 151 doi: 10.1517/13543780903501505
|
| 35 |
Asmaa M. Abdel-Aziz, Mohamed A. Ibrahim, Azza A. El-Sheikh, Maha Y. Kamel, Nagwa M. Zenhom, Salam Abdel-Raheim, Hisham Abdelhaleem. Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis. Journal of Clinical and Experimental Hepatology 2018; 8(1): 15 doi: 10.1016/j.jceh.2017.06.006
|
| 36 |
Robert A. Fridell, Dike Qiu, Chunfu Wang, Lourdes Valera, Min Gao.
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an
In Vitro
Replicon System
. Antimicrobial Agents and Chemotherapy 2010; 54(9): 3641 doi: 10.1128/AAC.00556-10
|